Leonie Deßloch

Leonie Deßloch

Auto-generated profile, based on publicly available information

Leonie Deßloch

Faculty for Chemistry and Pharmacy Ludwig‐Maximilians‐Universität München Butenandtstraße 5‐13, Haus B 81377 München Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2024 in Advanced NanoBiomed Research
Verified
Journal Article
Open access
FHFabio Henkel
Fabio Henkel
LDLeonie Deßloch
Leonie Deßloch
UGUfuk Gürer
Ufuk Gürer
BWBenjamin Winkeljann
Benjamin Winkeljann
MMMatthias Marczynski
Matthias Marczynski
OLOliver Lieleg
Oliver Lieleg
In recent years, highly specialized nanoscopic drug carriers have been developed, which can, e.g., traverse biological barriers, protect drugs against harsh physiological conditions, and release such drugs in a controlled manner. However, for the delivery of particles via the respiratory pathway, aerodynamic diameters in the range of several micrometers are required to achieve good lung deposition and biodistribution. To combine the favorable properties of inhalable, micron‐sized particles with the advantages of nanosized drug carriers, herein, dry‐powder, hybrid microparticles (h‐μPs), which disintegrate upon contact with moist surfaces (as present in the lung) to release the embedded nanoparticles into the mucosa, are introduced. Furthermore, a microfluidic setup, which mimics the air–gel interface of the mucosal airway epithelium, is presented. With this setup, the interaction of airborne h‐μPs with the mucosal interface on a microscopic level is investigated. In detail, the influence of the h‐μP charge on their deposition efficiency is tested and it is found that this process is governed by a combination of electrostatic interactions between the mucosal surface and the h‐μPs as well as hygroscopic effects. Thus, this approach can help to optimize inhalable drug carriers to increase the efficiency of pulmonary drug administration via the respiratory pathway.

1 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
LDLeonie Deßloch
Leonie Deßloch
DJDavid C. Jürgens
David C. Jürgens
KSKatharina Schäfer
Katharina Schäfer
EJEvalyne M. Jansen
Evalyne M. Jansen
HFHenderik W. Frijlink
Henderik W. Frijlink
Olivia M MerkelOlivia M Merkel
Olivia M Merkel
The advancement of RNA therapeutics, particularly small interfering RNA (siRNA), offers promising new approaches for the treatment of pulmonary diseases driven by aberrant gene expression and chronic inflammation like asthma and COPD. In this study, we systematically engineered dry powder inhaler (DPI) formulations containing low (0.8%) and high (2%) siRNA-loaded lipid nanoparticle (LNP) concentrations using spray drying. The matrix-forming excipients, lactose, mannitol and trehalose were combined with varying concentrations of L-leucine (3% to 30% relative to the sugar or sugar alcohol) and trileucine (3%) as dispersion enhancers. The goal was to address key formulation hurdles: maintaining siRNA gene-silencing efficiency, optimizing solid-state properties, and achieving efficient aerosolization for deep lung deposition.Lactose and trehalose-based spray-dried powders exhibited yields over 70% and preserved siRNA bioactivity, with gene silencing efficiencies exceeding 95% in vitro. Physicochemical characterization revealed that these formulations containing low to moderate leucine or trileucine content solidified in the glassy state, displaying glass transition temperatures over 76°C and residual moisture levels below 7%, favorable for long-term stability and pulmonary delivery. In contrast, mannitol-based formulations were highly crystalline and less compatible with LNPs, resulting in low yields, larger, irregular shaped particles and poor aerosolization efficiency. In vitro aerosol performance was assessed using two breath-actuated DPIs in a laser diffraction inhalation setup. Our findings highlight that successful pulmonary delivery of siRNA-LNP powders not only depend on powder attributes but also on the interplay between formulation and DPI device. Optimizing excipient selection with regard to a device’s powder dispersion principle is essential to achieve robust aerosol performance, efficient lung deposition, and preservation of therapeutic activity in solid-state siRNA-LNP dry powder formulations.

12 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SBSofia Bonsignore
Sofia Bonsignore
MJMin Jiang
Min Jiang
SDSalvatore Emanuele Drago
Salvatore Emanuele Drago
Cinzia SCIALABBACinzia SCIALABBA
Cinzia SCIALABBA
LDLeonie Deßloch
Leonie Deßloch
Gennara CavallaroGennara Cavallaro
Gennara Cavallaro
For the local treatment of lung diseases, siRNA inhalation could represent a promising approach, but it requires suitable formulations for efficient RNAi therapy. In this work, we developed a cationic and amphiphilic copolymer, obtained from the grafting on α,β-poly(N-2 hydroxyethyl)-DL-aspartamide (PHEA) of 1,2-Bis(3-aminopropylamino)ethane (bAPAE) and zein, with a derivatization degree (DD%), respectively, equal to 35 ± 0.3 mol% and 2.0 ± 0.2 mol%. The obtained graft PHEA-g-bAPAE-g-zein copolymer self-assembled in water and efficiently complexed siRNA. From this, nanoparticles (NPs) were produced by complexation with siRNA at N/P ratios of 10 and 20; by surface coating with phospholipid shell, polymer-lipid hybrid systems (LPHNPs) were also produced. These carriers showed nanometric size which was confirmed by TEM analysis. Nebulization with two commercial VMNs preserved the size and stability of most formulations, producing droplets suitable for inhalation (3.5–4.5 mm). Specifically, the Aerogen Solo device achieved higher product recovery than the Beurer IH 55. All samples, except for LPHNPs 10, demonstrated a high cellular uptake and efficient eGFP knockdown pre and post nebulization and mediated a sustained endosomal escape, validated through Pearson’s correlation coefficient analysis. LPHNPs 20 sample showed the highest eGFP knockdown of ~74% compared to the scrambled control sequence. Finally, the muco-diffusive properties, evaluated using two air-liquid interface (ALI) cellular models with different muco-secretory activity, showed that the LPHNPs 20 sample was the most internalized vector, as its diffusion and cellular uptake were less influenced by the amount of mucus on the cells.